BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.26B |
| 2 |
iShares MSCI ACWI ETF
ACWI
|
+$969M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$963M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$946M |
| 5 |
Microsoft
MSFT
|
+$803M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Home Depot
HD
|
+$219M |
| 2 |
Tesla
TSLA
|
+$156M |
| 3 |
FISV
Fiserv Inc
FISV
|
+$147M |
| 4 |
American Tower
AMT
|
+$134M |
| 5 |
Uber
UBER
|
+$114M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.18% |
| 2 | Financials | 8.26% |
| 3 | Consumer Discretionary | 5.82% |
| 4 | Healthcare | 4.57% |
| 5 | Communication Services | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PEI
3626
DELISTED
Pennsylvania Real Estate Investment Trust
PEI
| $20.4K | ﹤0.01% |
707
-280
| -28% | -$8.32K |
|
|
CHMA
3627
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $20.3K | ﹤0.01% |
6,496
-3,038
| -32% | -$11.7K |
|
|
SAGE
3628
DELISTED
Sage Therapeutics
SAGE
| $20.3K | ﹤0.01% |
271
-1,978
| -88% | -$162K |
|
3629
EVI Industries
EVI
$207M
| $20K | ﹤0.01% |
695
-301
| -30% | -$10.5K |
|
|
MBII
3630
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $19.9K | ﹤0.01% |
9,536
-486
| -5% | -$1.01K |
|
|
CASI
3631
DELISTED
CASI Pharmaceuticals
CASI
| $19.9K | ﹤0.01% |
828
-281
| -25% | -$7.89K |
|
|
LNAI
3632
Lunai Bioworks
LNAI
$10.5M
| $19.7K | ﹤0.01% |
69
+34
| +97% | +$9.99K |
|
|
TCDA
3633
DELISTED
Tricida, Inc. Common Stock
TCDA
| $19.3K | ﹤0.01% |
3,652
-1,707
| -32% | -$10.7K |
|
3634
Bank7 Corp
BSVN
$495M
| $19.2K | ﹤0.01% |
1,089
+400
| +58% | +$6.67K |
|
3635
TotalEnergies
TTE
$190B
| $19.2K | ﹤0.01% |
412
-83
| -17% | -$3.78K |
|
|
PVLA
3636
Palvella Therapeutics
PVLA
$2.28B
| $19.1K | ﹤0.01% |
93
-65
| -41% | -$14.2K |
|
3637
iRadimed
IRMD
$1.12B
| $19K | ﹤0.01% |
738
-412
| -36% | -$9.84K |
|
3638
CALL
Eli Lilly
LLY
$1.09T
| $18.7K | ﹤0.01% |
1
-140
| -99% | -$27.4K |
|
3639
Altisource Portfolio Solutions
ASPS
$64.2M
| $18.4K | ﹤0.01% |
251
+121
| +93% | +$10.1K |
|
3640
Pixelworks
PXLW
$42.1M
| $18.4K | ﹤0.01% |
462
-132
| -22% | -$5.5K |
|
3641
Atlanticus Holdings
ATLC
$1.5B
| $18.3K | ﹤0.01% |
602
-884
| -59% | -$24.5K |
|
3642
Maui Land & Pineapple Co
MLP
$317M
| $18.2K | ﹤0.01% |
1,578
+358
| +29% | +$4.21K |
|
|
OPTN
3643
DELISTED
OptiNose
OPTN
| $18.2K | ﹤0.01% |
328
-201
| -38% | -$12.2K |
|
|
ASPU
3644
DELISTED
ASPEN GROUP, INC.
ASPU
| $18.1K | ﹤0.01% |
3,021
-1,402
| -32% | -$12.6K |
|
|
AGRX
3645
DELISTED
Agile Therapeutics
AGRX
| $17.9K | ﹤0.01% |
4
-3
| -43% | -$16.2K |
|
|
SBBP
3646
DELISTED
Strongbridge Biopharma plc.
SBBP
| $17.8K | ﹤0.01% |
6,443
-3,240
| -33% | -$9.78K |
|
3647
Paysign
PAYS
$741M
| $17.7K | ﹤0.01% |
4,040
-1,585
| -28% | -$7.54K |
|
|
SECO
3648
DELISTED
Secoo Holding Limited ADR
SECO
| $17.6K | ﹤0.01% |
695
+204
| +42% | +$5.65K |
|
3649
Avalo Therapeutics
AVTX
$1.04B
| $17.4K | ﹤0.01% |
2
| – | – |
|
3650
Fennec Pharmaceuticals
FENC
$419M
| $17.4K | ﹤0.01% |
2,796
-1,420
| -34% | -$10.7K |
|
Similar funds
BNP Paribas Financial Markets's Q1 2021 Portfolio in Review
As of Q1 2021, BNP Paribas Financial Markets held 4,269 positions worth $68.3B, up 27% from $53.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
BNP Paribas Financial Markets deployed $15.9B of net new capital in Q1 2021, opening 125 new positions and adding to 2,252 existing holdings. Its largest new stake was State Street SPDR S&P Homebuilders ETF: 612,151 shares worth $43.1M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 8.2% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Home Depot, an estimated $219M trimmed.
- BNP Paribas Financial Markets's largest Q1 2021 buy was State Street SPDR S&P Homebuilders ETF: 612,151 shares worth $43.1M.
- BNP Paribas Financial Markets added most to Apple in Q1 2021, an estimated $1.26B increase.
- BNP Paribas Financial Markets's biggest Q1 2021 reduction was Home Depot, cutting an estimated $219M.
- BNP Paribas Financial Markets fully exited Lumen in Q1 2021, selling an estimated $9.65M.
- BNP Paribas Financial Markets's ten largest holdings make up 16% of its $68.3B portfolio in Q1 2021.
- BNP Paribas Financial Markets opened 125 new positions and closed 272 in Q1 2021.
- BNP Paribas Financial Markets's portfolio value rose 27% quarter-over-quarter to $68.3B.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2021, filed 7 May 2021.